{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:58:13Z","timestamp":1791899893278,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vancomycin is a commonly used antibiotic in critically ill patients for various indications. Critical illness imposes pharmacokinetic-pharmacodynamics challenges, which makes optimizing vancomycin in this population cumbersome. Data are scarce on the clinical impact of time to therapeutic trough levels of vancomycin in critically ill patients.  \u00a0This study aims to\u00a0evaluate the timing to achieve therapeutic trough level of\u00a0vancomycin on 30-day mortality in critically ill patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>A retrospective cohort study was conducted\u00a0for all adult critically ill patients with confirmed Gram-positive infection who received IV vancomycin between January 1, 2017, and December 31, 2020. We compared early (&lt;\u200948\u00a0h) versus late (\u2265\u200948\u00a0h) attainment of vancomycin therapeutic trough levels. The primary outcome was the 30-day mortality in critically ill patients. Secondary outcomes were the development of resistant organisms, microorganisms\u00a0eradication within 4\u20135\u00a0days of vancomycin initiation, acute kidney injury (AKI), and length of stay (LOS). Propensity score-matched (1:1 ratio) used based on patient\u2019s age, serum creatinine, and albumin\u00a0values at baseline.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 326 patients were included; 110 patients attained the therapeutic trough levels within 48\u00a0h of vancomycin initiation. Late achievement of the therapeutic\u00a0trough levels was associated with higher 30-day mortality (HR: 2.54; 95% CI [1.24\u20135.22]; p\u2009=\u20090.01). Additionally, patients who achieved therapeutic\u00a0trough levels of vancomycin late were more likely to develop AKI (OR\u2009=\u20092.59; 95% CI [1.01\u20136.65]; p\u2009=\u20090.04). Other outcomes were not statistically significant between the two groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Early achievement of vancomycin therapeutic levels in patients with confirmed Gram-positive infection was associated with possible survival benefits.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06840-y","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T13:02:46Z","timestamp":1637758966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The impact of early target attainment of vancomycin in critically ill patients with confirmed Gram-positive infection: A\u00a0retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Khalid","family":"Al Sulaiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alshaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohoud","family":"Aljuhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Alsaeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadiyah","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Vishwakarma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamdan","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Althewaibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nawaf","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alhelal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shmeylan","family":"Al Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"6840_CR1","doi-asserted-by":"publisher","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss RS, Moldawer LL, Opal SM, Reinhart K, Turnbull IR, Vincent JL. Sepsis and septic shock. Nat Rev Dis Primers. 2016;2:16045. https:\/\/doi.org\/10.1038\/nrdp.2016.45.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"6840_CR2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5005\/jp-journals-10071-23337","volume":"24","author":"Y Mehta","year":"2020","unstructured":"Mehta Y, Hegde A, Pande R, et al. Methicillin-resistant Staphylococcus aureus in Intensive Care Unit Setting of India: A Review of Clinical Burden, Patterns of Prevalence, Preventive Measures, and Future Strategies. Indian J Crit Care Med. 2020;24(1):55\u201362. https:\/\/doi.org\/10.5005\/jp-journals-10071-23337.","journal-title":"Indian J Crit Care Med"},{"key":"6840_CR3","first-page":"1","volume":"1","author":"FAS Aleidan","year":"2020","unstructured":"Aleidan FAS, Alkhelaifi H, Alsenaid A, et al. Incidence and risk factors of carbapenem-resistant Enterobacteriaceae infection in intensive care units: a matched case-control study. Expert Rev Anti Infect Ther. 2020;1:1\u20136.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"6840_CR4","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2147\/TCRM.S266295","volume":"16","author":"N Alshehri","year":"2020","unstructured":"Alshehri N, Ahmed AE, Yenugadhati N, et al. Vancomycin in ICU patients with gram-positive infections: Initial trough levels and mortality. Ther Clin Risk Manag. 2020;16:979\u201387.","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"6840_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099044","volume":"9","author":"Z Ye","year":"2014","unstructured":"Ye Z, Li C, Zhai S. Guidelines for therapeutic drug monitoring of vancomycin: a systematic review. PLoS ONE. 2014;9(6): e99044. https:\/\/doi.org\/10.1371\/journal.pone.0099044.","journal-title":"PLoS ONE"},{"key":"6840_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000459","author":"M Chuma","year":"2017","unstructured":"Chuma M, Makishima M, Imai T, et al. Relationship between initial vancomycin trough levels and early-onset vancomycin-associated nephrotoxicity in critically ill patients. Ther Drug Monit. 2017. https:\/\/doi.org\/10.1097\/ftd.0000000000000459.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"6840_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398.","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"6840_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/cid\/ciaa303","volume":"71","author":"MJ Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361\u20134.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"6840_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2012.02.010","volume":"39","author":"AA Udy","year":"2012","unstructured":"Udy AA, Roberts JA, Waele De, Jan J, Paterson DL, Lipman J. What\u2019s behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents. 2012;39(6):455\u20137. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.02.010.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"6840_CR10","doi-asserted-by":"publisher","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31. https:\/\/doi.org\/10.1186\/cc5713.","journal-title":"Crit Care"},{"key":"6840_CR11","unstructured":"The Clinical and Laboratory Standards Institute (CLSI) M60 ED2:2020 edition. Accessed 02 Sept 2021."},{"issue":"4","key":"6840_CR12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijantimicag.2011.05.013","volume":"38","author":"H Hanberger","year":"2011","unstructured":"Hanberger H, Walther S, Leone M, et al. Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents. 2011;38(4):331\u20135.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"6840_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1128\/CMR.05022-11.PMID:22491776;PMCID:PMC3346297","volume":"25","author":"SJ van Hal","year":"2012","unstructured":"van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012;25(2):362\u201386. https:\/\/doi.org\/10.1128\/CMR.05022-11.PMID:22491776;PMCID:PMC3346297.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"6840_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1111\/j.1365-2710.2004.00572.x","volume":"29","author":"A Vuagnat","year":"2004","unstructured":"Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther. 2004;29(4):351\u20137.","journal-title":"J Clin Pharm Ther."},{"issue":"2","key":"6840_CR15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1093\/jac\/35.2.352","volume":"35","author":"M Wysocki","year":"1995","unstructured":"Wysocki M, Thomas F, Wolff MA, Pean Y, Ravaud Y, Herman B. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother. 1995;35(2):352\u20134.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"6840_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1097\/TA.0000000000002492","volume":"87","author":"RD Villanueva","year":"2019","unstructured":"Villanueva RD, Talledo O, Neely S, et al. Vancomycin dosing in critically ill trauma patients: the VANCTIC study. J Trauma Acute Care Surg. 2019;87(5):1164\u201371.","journal-title":"J Trauma Acute Care Surg"},{"issue":"5","key":"6840_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1592\/phco.31.5.441","volume":"31","author":"R Kullar","year":"2011","unstructured":"Kullar R, Leonard SN, Davis SL, et al. Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15\u201320 mg\/L suggested by the vancomycin consensus guidelines. Pharmacotherapy. 2011;31(5):441\u20138.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"6840_CR18","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/000313481307901123","volume":"79","author":"TM Schmelzer","year":"2013","unstructured":"Schmelzer TM, Christmas AB, Norton HJ, Heniford BT, Sing RF. Vancomycin intermittent dosing versus continuous infusion for treatment of ventilator-associated pneumonia in trauma patients. Am Surg. 2013;79(11):1185\u201390.","journal-title":"Am Surg"},{"issue":"4","key":"6840_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.jiph.2015.01.011","volume":"8","author":"S Tafelski","year":"2015","unstructured":"Tafelski S, Nachtigall I, Troeger U, et al. Observational clinical study on the effects of different dosing regimens on vancomycin target levels in critically ill patients: continuous versus intermittent application. J Infect Public Health. 2015;8(4):355\u201363.","journal-title":"J Infect Public Health"},{"issue":"1","key":"6840_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jcrc.2012.02.003","volume":"28","author":"B Saugel","year":"2013","unstructured":"Saugel B, Nowack MCM, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care. 2013;28(1):9\u201313.","journal-title":"J Crit Care"},{"issue":"2","key":"6840_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1086\/524667","volume":"46","author":"A Soriano","year":"2008","unstructured":"Soriano A, Marco F, Mart\u00ednez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193\u2013200.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"6840_CR22","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1128\/AAC.00113-08","volume":"52","author":"TP Lodise","year":"2008","unstructured":"Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315\u201320.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"6840_CR23","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","volume":"166","author":"LK Hidayat","year":"2006","unstructured":"Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138\u201344.","journal-title":"Arch Intern Med"},{"issue":"6","key":"6840_CR24","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1177\/0897190019829652","volume":"33","author":"WB Hays","year":"2020","unstructured":"Hays WB, Tillman E. Vancomycin-associated acute kidney injury in critically ill adolescent and young adult patients. J Pharm Pract. 2020;33(6):749\u201353.","journal-title":"J Pharm Pract"},{"issue":"7","key":"6840_CR25","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1128\/AAC.00173-11","volume":"55","author":"E Minejima","year":"2011","unstructured":"Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-Beringer A. Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients. Antimicrob Agents Chemother. 2011;55(7):3278\u201383.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"6840_CR26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","volume":"29","author":"MN Jeffres","year":"2007","unstructured":"Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107\u201315.","journal-title":"Clin Ther"},{"issue":"1","key":"6840_CR27","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2050-6511-14-12","volume":"14","author":"RG Hall 2nd","year":"2013","unstructured":"Hall RG 2nd, Hazlewood KA, Brouse SD, et al. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study. BMC Pharmacol Toxicol. 2013;14(1):12.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"6840_CR28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/ALN.0b013e3181a97272","volume":"111","author":"D Hutschala","year":"2009","unstructured":"Hutschala D, Kinstner C, Skhirdladze K, Thalhammer F, M\u00fcller M, Tschernko E. Influence of vancomycin on renal function in critically ill patients after cardiac surgery: continuous versus intermittent infusion: Continuous versus intermittent infusion. Anesthesiology. 2009;111(2):356\u201365.","journal-title":"Anesthesiology"},{"issue":"12","key":"6840_CR29","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1097\/CCM.0000000000000514","volume":"42","author":"TP Hanrahan","year":"2014","unstructured":"Hanrahan TP, Harlow G, Hutchinson J, et al. Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis. Crit Care Med. 2014;42(12):2527\u201336.","journal-title":"Crit Care Med"},{"issue":"2","key":"6840_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s11739-020-02287-2","volume":"15","author":"T Ciarambino","year":"2020","unstructured":"Ciarambino T, Giannico OV, Campanile A, Tirelli P, Para O, Signoriello G, Giordano M. Acute kidney injury and vancomycin\/piperacillin\/tazobactam in adult patients: a systematic review. Intern Emerg Med. 2020;15(2):327\u201331. https:\/\/doi.org\/10.1007\/s11739-020-02287-2 (Epub 2020 Feb 10 PMID: 32040830).","journal-title":"Intern Emerg Med"},{"issue":"1","key":"6840_CR31","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/neu.2015.4328","volume":"34","author":"AA Udy","year":"2017","unstructured":"Udy AA, Jarrett P, Lassig-Smith M, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. J Neurotrauma. 2017;34(1):137\u201344. https:\/\/doi.org\/10.1089\/neu.2015.4328.","journal-title":"J Neurotrauma"},{"issue":"4","key":"6840_CR32","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1097\/TA.0000000000001387","volume":"82","author":"JF Barletta","year":"2017","unstructured":"Barletta JF, Mangram AJ, Byrne M, et al. Identifying augmented renal clearance in trauma patients: validation of the augmented renal clearance in trauma intensive care scoring system. J Trauma Acute Care Surg. 2017;82(4):665\u201371. https:\/\/doi.org\/10.1097\/TA.0000000000001387.","journal-title":"J Trauma Acute Care Surg"},{"issue":"3","key":"6840_CR33","doi-asserted-by":"publisher","first-page":"111","DOI":"10.12793\/tcp.2018.26.3.111","volume":"26","author":"AJ Atkinson Jr","year":"2018","unstructured":"Atkinson AJ Jr. Augmented renal clearance. Transl Clin Pharmacol. 2018;26(3):111\u20134. https:\/\/doi.org\/10.12793\/tcp.2018.26.3.111.","journal-title":"Transl Clin Pharmacol"},{"issue":"11","key":"6840_CR34","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1097\/CCM.0000000000005357","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, et al. Executive summary: surviving sepsis campaign: international guidelines for the management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):1974\u201382. https:\/\/doi.org\/10.1097\/CCM.0000000000005357.","journal-title":"Crit Care Med"},{"issue":"1","key":"6840_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40064-015-1146-9","volume":"4","author":"AP Cardile","year":"2015","unstructured":"Cardile AP, Tan C, Lustik MB, Stratton AN, Madar CS, Elegino J, Hsue G. Optimization of time to initial vancomycin target trough improves clinical outcomes. Springerplus. 2015;4(1):1\u201314.","journal-title":"Springerplus"},{"issue":"supp_1","key":"6840_CR36","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1093\/cid\/cit614","volume":"58","author":"KA Rodvold","year":"2014","unstructured":"Rodvold KA, Mconeghy KW. Methicillin-resistant Staphylococcus aureus therapy: past, present, and future. Clin Infect Dis. 2014;58(supp_1):S20\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"6840_CR37","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4161\/viru.23724","volume":"4","author":"SM Soto","year":"2013","unstructured":"Soto SM. Role of efflux pumps in the antibiotic resistance of bacteria embedded in a biofilm. Virulence. 2013;4(3):223\u20139.","journal-title":"Virulence"},{"issue":"24","key":"6840_CR38","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.2174\/1568026620666200704135837","volume":"20","author":"KL Monteiro","year":"2020","unstructured":"Monteiro KL, de Aquino TM, Mendon\u00e7a Junior FJB. An update on Staphylococcus aureus NorA efflux pump inhibitors. Curr Top Med Chem. 2020;20(24):2168\u201385.","journal-title":"Curr Top Med Chem"},{"issue":"02","key":"6840_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.3855\/jidc.11102","volume":"13","author":"D Usai","year":"2019","unstructured":"Usai D, Donadu M, Bua A, Molicotti P, Zanetti S, Piras S, et al. Enhancement of antimicrobial activity of pump inhibitors associating drugs. J Infect Dev Count. 2019;13(02):162\u20134.","journal-title":"J Infect Dev Count"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06840-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06840-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T13:03:08Z","timestamp":1637758988000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06840-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6840"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06840-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]},"assertion":[{"value":"29 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved on November 2020, by King Abdullah International Medical Research Center (KAIMRC)-Institutional Review Board (IRB), Riyadh, Saudi Arabia (Reference No: RC20\/587\/R). All methods were performed in accordance with relevant guidelines and regulations. Participants\u2019 confidentiality was strictly observed throughout the study by using anonymous unique serial number for each subject and restricting data only to the investigators. KAIMRC-IRB committee waived the informed consent due to its retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No author has a conflict of interest in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1182"}}